Blaze Bioscience, Inc., a Seattle, WA-based biotechnology company that develops technology for real-time, high-resolution visualization of a broad array of solid tumors, has raised $5m in Series A financing.
Led by Heather Franklin, Co-Founder, President and CEO, Blaze Bioscience is developing Tumor Paint technology for real-time, high-resolution visualization of a broad array of solid tumors.
Originated in and licensed from the laboratory of one of the co-founders of the company, Dr. Jim Olson of the Fred Hutchinson Cancer Research Center, Tumor Paint aims to enable surgeons to see and remove cancerous tissue that might have otherwise been undetected.
The company intends to use the funding to further advance its technology, from the seed stage to full execution mode moving it into development, including product scale up and toxicology studies.
FinSMEs
08/06/2012